Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary T Ferguson

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Thorax|August 6, 2010
Cardiovascular events in patients with COPD: TORCH study resultsPeter M A Calverley, Julie A Anderson, Bartolome Celli, et al.
Respiratory Physiology & Neurobiology|February 14, 2018
Effect of tiotropium on spontaneous expiratory flow-volume curves during exercise in GOLD 1-2 COPDJanos Porszasz, Nicolò Carraro, Robert Cao, et al.
Advances in Therapy|November 11, 2020
Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO<sup>®</sup> TrialsKlaus F Rabe, James D Chalmers, Marc Miravitlles, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|December 21, 2019
Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthmaArnaud Bourdin, Dominick Shaw, Andrew Menzies-Gow, et al.
American Journal of Respiratory and Critical Care Medicine|September 4, 2010
Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experienceBartolome Celli, Jörgen Vestbo, Christine R Jenkins, et al.
American Journal of Respiratory and Critical Care Medicine|May 31, 2008
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyBartolomé R Celli, Nicola E Thomas, Julie A Anderson, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|June 4, 2009
Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ)William C Bailey, Frank C Sciurba, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|September 21, 2018
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trialGary T Ferguson, Klaus F Rabe, Fernando J Martinez, et al.
Respiratory Medicine|October 13, 2019
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocolKlaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Lancet (London, England)|September 10, 2016
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialJ Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Thorax|August 6, 2010
Cardiovascular events in patients with COPD: TORCH study resultsPeter M A Calverley, Julie A Anderson, Bartolome Celli, et al.
Respiratory Physiology & Neurobiology|February 14, 2018
Effect of tiotropium on spontaneous expiratory flow-volume curves during exercise in GOLD 1-2 COPDJanos Porszasz, Nicolò Carraro, Robert Cao, et al.
Advances in Therapy|November 11, 2020
Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO<sup>®</sup> TrialsKlaus F Rabe, James D Chalmers, Marc Miravitlles, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|December 21, 2019
Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthmaArnaud Bourdin, Dominick Shaw, Andrew Menzies-Gow, et al.
American Journal of Respiratory and Critical Care Medicine|September 4, 2010
Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experienceBartolome Celli, Jörgen Vestbo, Christine R Jenkins, et al.
American Journal of Respiratory and Critical Care Medicine|May 31, 2008
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyBartolomé R Celli, Nicola E Thomas, Julie A Anderson, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|June 4, 2009
Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ)William C Bailey, Frank C Sciurba, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|September 21, 2018
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trialGary T Ferguson, Klaus F Rabe, Fernando J Martinez, et al.
Respiratory Medicine|October 13, 2019
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocolKlaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Lancet (London, England)|September 10, 2016
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialJ Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, et al.
Pageof 11